Extrait

To compare the overall survival associated with vorinostat plus best supportive care versus that associated with placebo plus best supportive care for the treatment of patients with advanced malignant pleural mesothelioma who have failed at least one prior chemotherapy regimen, and to determine the overall safety and toxicity of vorinostat in this population.

Critère d'inclusion

• Mesothelioma

Liens

• euctr
• euctr
• ictrp
• ictrp
• ictrp
• ictrp
• ictrp
• euctr
• euctr
• euctr
• euctr
• euctr
• euctr
• ictrp
• ictrp
• ictrp